ATE270325T1 - Rückgewinnung von viren aus zellkulturen durch verwendung einer hypertonischen salzlösung - Google Patents

Rückgewinnung von viren aus zellkulturen durch verwendung einer hypertonischen salzlösung

Info

Publication number
ATE270325T1
ATE270325T1 AT98938765T AT98938765T ATE270325T1 AT E270325 T1 ATE270325 T1 AT E270325T1 AT 98938765 T AT98938765 T AT 98938765T AT 98938765 T AT98938765 T AT 98938765T AT E270325 T1 ATE270325 T1 AT E270325T1
Authority
AT
Austria
Prior art keywords
virus
salt solution
viruses
recovery
cell cultures
Prior art date
Application number
AT98938765T
Other languages
English (en)
Inventor
Michael Denis Johnston
Roderic Simon O'keeffe
Original Assignee
Xenova Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10817061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE270325(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xenova Res Ltd filed Critical Xenova Res Ltd
Application granted granted Critical
Publication of ATE270325T1 publication Critical patent/ATE270325T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98938765T 1997-08-07 1998-08-07 Rückgewinnung von viren aus zellkulturen durch verwendung einer hypertonischen salzlösung ATE270325T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9716611.0A GB9716611D0 (en) 1997-08-07 1997-08-07 Virus preparations and methods
PCT/GB1998/002387 WO1999007834A1 (en) 1997-08-07 1998-08-07 Recovery of virus from cell culture using a hypertonic salt solution

Publications (1)

Publication Number Publication Date
ATE270325T1 true ATE270325T1 (de) 2004-07-15

Family

ID=10817061

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98938765T ATE270325T1 (de) 1997-08-07 1998-08-07 Rückgewinnung von viren aus zellkulturen durch verwendung einer hypertonischen salzlösung

Country Status (11)

Country Link
EP (1) EP1002055B2 (de)
JP (2) JP2001512675A (de)
AT (1) ATE270325T1 (de)
AU (1) AU8737298A (de)
CA (1) CA2299628A1 (de)
DE (1) DE69824856T2 (de)
DK (1) DK1002055T3 (de)
ES (1) ES2224422T3 (de)
GB (1) GB9716611D0 (de)
PT (1) PT1002055E (de)
WO (1) WO1999007834A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2330202T5 (es) 2001-09-06 2014-01-20 Alphavax, Inc. Sistemas vectores basados en replicones de alfavirus
US7078218B2 (en) * 2002-12-13 2006-07-18 Alphavax, Inc. Alphavirus particles and methods for preparation
US7442381B2 (en) 2003-03-20 2008-10-28 Alphavax, Inc. Alphavirus replicons and helper constructs
CA2503774C (en) 2003-06-20 2007-09-25 Microbix Biosystems Inc. Improvements in virus production
CN100398642C (zh) * 2003-06-20 2008-07-02 迈克必斯生物系统公司 病毒生产的改进
DE602004021260D1 (de) 2003-07-11 2009-07-09 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
US8460913B2 (en) 2007-06-21 2013-06-11 Alpha Vax, Inc. Promoterless cassettes for expression of alpha virus structural proteins
US9809800B2 (en) 2012-11-22 2017-11-07 Asahi Kasei Medical Co., Ltd. Method for producing parvovirus having high infectivity titer
CN104250639A (zh) * 2013-06-28 2014-12-31 北京奥源和力生物技术有限公司 一种收获和生产病毒的方法
EP3372677B8 (de) 2015-11-06 2019-09-25 Asahi Kasei Medical Co., Ltd. Verfahren zur herstellung eines parvovirus mit hohem infektiositätstiter und hoher reinheit
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
US20220010286A1 (en) * 2020-07-10 2022-01-13 Boehringer Ingelheim International Gmbh Process for producing a purified rhabdovirus from cell culture

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204257A (en) * 1991-04-29 1993-04-20 Autogen Instruments, Inc. Method of recovering bacteriophage
CA2097019C (en) * 1992-06-04 2007-07-24 Philip J. Provost Process for attenuated varicella zoster virus vaccine production

Also Published As

Publication number Publication date
EP1002055A1 (de) 2000-05-24
AU8737298A (en) 1999-03-01
ES2224422T3 (es) 2005-03-01
CA2299628A1 (en) 1999-02-18
PT1002055E (pt) 2004-10-29
DK1002055T3 (da) 2004-10-25
DE69824856D1 (de) 2004-08-05
JP2009297036A (ja) 2009-12-24
JP2001512675A (ja) 2001-08-28
EP1002055B1 (de) 2004-06-30
DE69824856T2 (de) 2005-07-21
GB9716611D0 (en) 1997-10-08
EP1002055B2 (de) 2010-04-14
WO1999007834A1 (en) 1999-02-18

Similar Documents

Publication Publication Date Title
DE69824856D1 (de) Rückgewinnung von viren aus zellkulturen durch verwendung einer hypertonischen salzlösung
CY1114598T1 (el) Μεθοδος για την ενισχυση ενος ιου φυσαλιδωδους νοσου υπο συνθηκες ελευθερες ορου
ATE286537T1 (de) Vakzinproduktion
ATE466932T1 (de) Vermehrung von viren in zellkultur
EA199800746A1 (ru) Способ генерации противовирусного иммунного ответа у человека или животного
HUP0000992A2 (hu) Sejttenyészetben szaporodni képes, géntechnológiailag módosított, fertőző nyálkatömlő-betegséget okozó vírus (IBDV) mutánsai
DiGiacomo et al. Viral diseases
ATE205536T1 (de) Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe
EA200300215A1 (ru) Вакцинация против вирусов герпеса, ассоциированных с хозяйской клеткой
US4115195A (en) Rabies vaccine preparation
NL174371C (nl) Rabiesvirus; uit dit virus bereid vaccin alsmede lokaas waarin dit vaccin is opgenomen.
Groupe et al. Ingestion and Destruction of Influenza Virus by Free Living Ciliate Tetrahymena pyrifortnis
ATE284709T1 (de) Virale chimären aus caev und hiv-1 genetischen elementen
JP6708636B2 (ja) Ｂｓｔ２遺伝子の機能が喪失された細胞株を利用したウィルス感染促進及び産生増進方法
DE69916022D1 (de) Verwendung von il-11 zur verstärkung der zellvermittelten immunität zur behandlung verschiedener viraler und parasitärer infektionen und krebs
EP2606128A1 (de) Permanente humane amniozyten zelllinie zur herstellung von influenzaviren
CN105561303B (zh) 单纯疱疹病毒i型ul5基因缺失的dna疫苗的制备方法
Nishibe et al. Induction of SMON-type virus from avian infectious laryngotracheitis virus
RU2022132198A (ru) Живой аттенуированный штамм вируса желтой лихорадки, адаптированный к росту в клетках vero, и вакцинная композиция, содержащая его
EP1327687A4 (de) Verfahren zur infektion des hepatitis c viruses
SU1081208A1 (ru) Способ выращивани ортомиксовирусов
RU94031386A (ru) Вакцина сухая культуральная против вирусного энтерита гусей и способ профилактики и лечения вирусного энтерита гусей
TH31643A (th) การปรับปรุงเซลล์ ไลน์ที่สนับสนุนสำหรับการผลิตวัคซีนป้องกันโรคมาเรกส์
RU2000125010A (ru) Способ получения бивалентной вакцины против болезни марека
JPS6485092A (en) Production of protein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1002055

Country of ref document: EP

RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties